BAFNAPH — BAFNA Pharmaceuticals Balance Sheet
0.000.00%
- IN₹4.37bn
- IN₹4.62bn
- IN₹1.46bn
- 54
- 10
- 89
- 51
Annual balance sheet for BAFNA Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | R2022 March 31st | 2023 March 31st | C2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 18 | 1.73 | 78.1 | 14 | 34.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 95.6 | 155 | 559 | 615 | 521 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 497 | 509 | 873 | 938 | 847 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 368 | 388 | 402 | 507 | 661 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 865 | 901 | 1,296 | 1,477 | 1,531 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 243 | 220 | 465 | 541 | 519 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 297 | 282 | 561 | 668 | 683 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 568 | 620 | 735 | 808 | 848 |
| Total Liabilities & Shareholders' Equity | 865 | 901 | 1,296 | 1,477 | 1,531 |
| Total Common Shares Outstanding |